Agenus Inc

NASDAQ:AGEN   3:59:55 PM EDT
5.30
+0.12 (+2.32%)
Products

Agenus Announces U.S. FDA Acceptance And Priority Review Of Balstilimab Biologics License Application For The Treatment Of Recurrent Or Metastatic Cervical Cancer

Published: 06/17/2021 13:02 GMT
Agenus Inc (AGEN) - Agenus Announces U.S. FDA Acceptance and Priority Review of Balstilimab Biologics License Application for the Treatment of Recurrent Or Metastatic Cervical Cancer.
Agenus Inc - Under Prescription Drug User Fee Act (pdufa), FDA Has Set a Target Action Date of December 16, 2021 for Balstilimab Bla.